AGP Executive Report
Last update: 9 hours agoGLP-1 and movement: New ENDO 2026 research in Chicago finds people taking Ozempic and similar weight-loss drugs became less physically active, raising concerns about lean muscle loss even as weight drops. Sugar-free diets under scrutiny: Also at ENDO 2026, animal work suggests fully cutting sucrose can disrupt gut health and worsen metabolic markers, pointing to “balance over elimination.” Infant chemical exposure: A LIFE-MILCH study presented at ENDO 2026 detected endocrine-disrupting chemicals in breast milk and in infant urine up to six months, highlighting early-life vulnerability. Diabetes risk tech: ENDO 2026 also featured a plasma “messenger” study using extracellular vesicles to predict type 1 diabetes risk before symptoms. Autonomy push in Illinois: Rivian CEO RJ Scaringe says the company is targeting an increasingly driverless, Tesla-like experience, with unsupervised driving aimed for next year, building on its Normal, Illinois ramp. Illinois policy: Illinois distributed $25M to local pharmacies, and the state launched a free statewide digital library service to expand access to research and education. Legal fight over pesticides: Pesticide makers are lobbying for “liability shield” laws as the Supreme Court weighs whether federal law blocks state failure-to-warn lawsuits tied to glyphosate.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
